What Butazolidina Treats: Main Uses and Benefits

The therapeutic framework for Butazolidina is considered relevant in contexts involving heightened systemic burden and significant symptom expression. The active component is commonly used to help with acute and chronic inflammatory conditions.

Butazolidina is primarily used to address symptoms related to physical discomfort and inflammatory or irritative states in conditions such as Gouty Arthritis and symptoms linked to chronic rheumatic disorders, including Ankylosing Spondylitis and Rheumatoid Arthritis. It is also commonly used across conditions presenting with acute episodes, such as Bursitis, Tendonitis, or Sprains and Strains. The active substance was historically relevant for symptomatic management in acute rheumatism, gout, and various other rheumatoid diseases in man.

The therapeutic benefit provides support that helps ease the overall symptom burden during difficult episodes. The medication is used in areas where additional symptomatic support is needed and contributes to improved day-to-day comfort during periods of heightened symptoms by assisting with the overall load of chronic inflammatory symptoms.

---

Quick Fact: Support for Symptoms that Create Functional Strain Butazolidina is used in areas where additional symptomatic support is needed, applying to symptoms that create noticeable functional strain and affect functional stability.

---

Regulatory References

1. NIH DailyMed entry on Phenylbutazone

Who can and cannot use Butazolidina? (Phenylbutazone)

The drug phenylbutazone (historically sold as Butazolidina in some markets) is not approved or marketed for human use in the United States (FDA) due to the risk of severe blood disorders, such as aplastic anemia, and other serious adverse effects. Its primary use is in veterinary medicine.

Eligibility Restrictions (Human and Animal)

Category	Status/Rule (Based on Official Regulatory Documents)
Humans	Not for Use in Humans (Prohibited in the U.S.).
Age	Contraindicated in children 14 years of age or less and senile (elderly) patients (where human use is permitted).
Conditions	Contraindicated in individuals with a history of blood dyscrasias (e.g., severe hematological conditions), peptic ulcer or active inflammatory gastrointestinal disease, or severe hepatic, cardiac, or renal dysfunction (where human use is permitted).
Hypersensitivity	Contraindicated in those with known hypersensitivity to phenylbutazone or other non-steroidal anti-inflammatory drugs (NSAIDs).
Pregnancy/Lactation	Use is not recommended during pregnancy and breastfeeding.
Food-Producing Animals	Prohibited for use in animals intended for human consumption (meat, milk, or eggs) due to zero-tolerance for residues. Specifically, its use is prohibited in female dairy cattle 20 months of age or older.

Interactions with other medicines and products

Official regulatory documents classify several clinically significant interaction patterns for Butazolidina (Phenylbutazone). Co-administration with Oral Anticoagulants (e.g., Warfarin) is restricted because Phenylbutazone is documented to potentiate the hypoprothrombinemic effect and displace the anticoagulant from plasma protein binding sites, resulting in a substantially increased risk of hemorrhage. The risk of hemorrhagic peptic ulcers is officially noted as higher for elderly or debilitated patients in this combination.

Co-use with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) is generally prohibited, with a regulatory requirement that Butazolidina must not be administered concurrently or within 24 hours of other NSAIDs to avoid additive toxicity. The combination with Oral Corticosteroids similarly increases the documented risk of gastrointestinal bleeding.

Butazolidina is documented to affect the exposure of several medicines. It can induce hepatic microsomal enzyme activity, altering the clearance of co-administered medicines, and it may raise the blood levels of agents like Phenytoin and Valproic Acid. The combination with Sulfonylurea Antidiabetic Agents (e.g., Chlorpropamide) is associated with an increased risk of hypoglycemia. Furthermore, Alcohol consumption is officially identified as a factor that increases the risk of gastrointestinal bleeding associated with this medicine.

How Butazolidina Works: Mechanism of Action

Targeting the Eicosanoid Pathway via Enzyme Blockade

The primary action of Butazolidina is achieved by acting as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This mechanism acts within the eicosanoid synthesis pathway, blocking the initial step of converting arachidonic acid into pro-inflammatory mediators known as prostaglandins. This molecular interaction alters early steps in the signaling cascade that precedes systemic physiological responses.

️ Modulating Peripheral and Central Signaling Responses

By preventing prostaglandin synthesis, the drug modulates two critical physiological responses. Peripherally, it limits the chemical sensitization of pain-sensing nerves, resulting in reduced afferent neural signaling from peripheral nociceptors. Centrally, it supports the regulation of the thermoregulatory set point in the hypothalamus, facilitating the restoration of the hypothalamic thermoregulatory set point when it is elevated. These actions engage mechanisms that influence feedback regulation within the affected systems.

Prolonged Action through Active Metabolites

The overall mechanistic profile is influenced by a multi-component mechanism, as the parent drug is metabolized into an active compound, Oxyphenbutazone. This compound retains the inhibitory effect on COX enzyme activity. This combined activity extends the duration of eicosanoid pathway modulation, influencing the overall temporal pattern of the mechanistic effect.

How Butazolidina is Used

Butazolidina (Phenylbutazone) is utilized strictly according to administration protocols, which mandate short-term therapy, precise dosing, and specific intake conditions. The use of this medication is characterized by a rapid initiation of therapy and immediate dose reduction upon clinical response, as detailed in prescribing information.

---

Administration Routes and Dosing Strategy

The medication is officially administered via the oral route (tablets/capsules) and the rectal route (suppositories). In controlled settings, it may also be given via parenteral injection (e.g., deep intramuscular injection).

Usage follows a defined two-stage dosing regimen:

Regimen Stage	Typical Daily Dose Range	Frequency Pattern
Initial (Loading) Dose	300 mg to 600 mg	Divided into 3 to 4 doses
Maintenance Dose	100 mg to 400 mg	Divided into 2 to 4 doses

The maximum recommended daily dose after the first day is generally 400 mg. The dose must be lowered to the minimum effective level immediately following any sign of symptom relief.

---

Administration Conditions and Duration

Oral dosage forms must be taken with or immediately following food or a full glass of milk. This instruction is a necessary condition for proper administration.

Treatment must be strictly limited in duration, typically not exceeding 7 consecutive days for acute flare-ups. If no discernible clinical response is evident within three to four days, the administration of the medicine must be discontinued to align with official use constraints.

Butazolidina: Recent Clinical Evidence

The foundation of research for Butazolidina (Phenylbutazone) largely consists of historical clinical trials and comparative studies conducted during the mid-20th century. This evidence base focuses primarily on short-term outcomes in specific inflammatory conditions. This evidence contextualizes what is known about its study in humans, as well as where limitations and uncertainties exist in the current research record.

Evidence Landscape and Limitations

Research has historically explored the use of Butazolidina in contexts like Acute Gouty Arthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. In these settings, study designs included short-term Randomized Controlled Trials (RCTs) and double-blind crossover studies. Researchers examined measurements related to physical discomfort and functional measures, monitoring changes in pain, inflammation, stiffness, and mobility over defined time intervals.

The findings describe patterns observed in symptomatic response over short observation periods, often lasting only a few weeks. The evidence is derived from settings with varying symptom burdens.

Uncertainty and Gaps

The core limitation of the research record is its age. Evidence quality varies across studies, and many older trials did not meet current methodological standards. Comparative evidence is lacking against the full range of modern therapeutic options. Data for certain groups, including children, older adults, or those with various comorbid conditions, remain limited.

Crucially, long-term findings are not fully established. The follow-up durations were limited, meaning there is insufficient information regarding the durability of any reported symptomatic changes or its association with long-term disease modification. Overall, the level of certainty regarding sustained, long-term outcomes remains limited due to the age and scope of the evidence.

Key Studies & References

1. Clinical studies of phenylbutazone (butazolidin) and butapyrin (irgapyrin) in rheumatoid arthritis, rheumatoid spondylitis, and gout
2. Phenylbutazone: FDA label (Animal Drug) - Example of regulatory status reflecting human withdrawal and warnings

Common questions about Butazolidina (FAQ)

Q: Is Butazolidina still available for prescription today?

Regulatory documents in the United States specify that this medicine is not approved or marketed for human use in that country due to safety concerns. Its primary use is documented as being in veterinary medicine. Availability for human prescription is highly restricted and varies depending on the official regulations of individual countries.

Q: How is Butazolidina different from ibuprofen or naproxen?

Butazolidina (Phenylbutazone) is classified as an NSAID (Nonsteroidal Anti-inflammatory Drug), but it belongs to a distinct category known as a pyrazolone derivative. Official documents note this classification is associated with a distinct pharmacological profile and that the drug exhibits anti-inflammatory properties.

Q: What are the common side effects of Butazolidina?

Official product information focuses heavily on documenting rare but severe adverse reactions. However, some officially noted less severe reactions that may occur include symptoms like upset stomach or throwing up.

Q: Does taking Butazolidina long-term increase certain risks?

Regulatory warnings explicitly indicate that the risks of certain severe complications may be greater with long-term use of this medication. These documented risks include heart and blood vessel problems, as well as severe stomach or bowel issues like ulcers or bleeding. For this reason, official protocols typically require that the duration of treatment be strictly limited.

Q: What should I look out for as a sign of an allergic reaction to Butazolidina?

Official safety information lists several potential signs of an allergic reaction or hypersensitivity. These documented signs include rash, hives, itching, swelling of the face, lips, tongue, or throat, wheezing, or difficulty with breathing or swallowing.

Q: Does Butazolidina interact with common blood pressure medications?

Yes, official interaction documents indicate that this medicine can influence how some blood pressure medications work. Co-administration may reduce the antihypertensive, or blood pressure lowering, effect of certain drugs, including classes like ACE inhibitors, beta-blockers, and diuretics.

Q: How long after taking a dose of Butazolidina does its effect typically begin?

Official administration and clinical documentation generally describe the response to therapy as being prompt. The onset of a noticeable effect is usually stated to occur within 24 hours of the medicine being administered.

Q: What are the signs of liver complications associated with Butazolidina?

Official safety warnings cite specific signs that may indicate possible liver problems. These signs include the yellowing of the skin or eyes (jaundice), dark urine, feeling tired, loss of appetite, stomach pain, or the presence of light-colored stools.

Q: Does Butazolidina affect the effectiveness of birth control?

Limited clinical data referenced in drug interaction documents suggest that this medicine may reduce the effectiveness of hormonal contraceptives. This potential is due to the drug possibly altering the levels of contraceptive hormones.

Q: Does Butazolidina have a Black Box Warning in the official drug labeling?

Official regulatory documents contain prominent, boxed warnings regarding the potential for serious adverse effects. These warnings highlight significant risks, including the potential for severe blood disorders and an increased risk of cardiovascular and gastrointestinal events.

Q: What are the known effects of Butazolidina on the eyes?

Safety documentation for the raw substance or formulation contains warnings that Phenylbutazone causes serious eye irritation upon direct contact. Additionally, some rare but serious systemic adverse reactions, such as Stevens-Johnson syndrome, are officially associated with ocular involvement.

Q: Does Butazolidina need to be gradually stopped when discontinuing use?

Official administration guidelines emphasize a cautious approach to dosage changes. Following the initial high-dose phase, the dose is stated to be reduced gradually to the lowest effective maintenance level to help achieve the lowest effective maintenance level, according to official administration guidelines.

Q: What official organizations regulate the use of Butazolidina?

This medicine is subject to regulatory oversight by governmental health authorities in every jurisdiction where it is approved. Examples of these organizations include the U.S. Food and Drug Administration (FDA), which sets and enforces strict regulatory and usage constraints on the drug.

How to Store and Dispose of Butazolidina?

Official regulatory documents define strict environmental and handling requirements for Phenylbutazone (Butazolidina) to ensure product stability and safety.

Official Storage Requirements

Constraint	Requirement	Applicable Form
Temperature	Store in a refrigerator: 2 C to 8 C	Injectable Solution
Light	Product must be protected from light	Injectable Solution
Container	Must be kept tightly closed	All Forms
Stability	Use within 28 days of first opening	Injectable Solution
Prohibited	Keep away from heat and sources of ignition	All Forms

Disposal and Safety

It is mandatory to keep Butazolidina out of the sight and reach of children.

Disposal of unused or expired product must follow official regulatory guidelines, which typically prioritize returning the medication to a certified drug take-back collection site. The product should not be released to the environment or disposed of via wastewater.